AOD-9604 protocol · PepGuide

Check your units. The units in this table assume 2.5 mg/mL, but the guide's recommended mix makes 5 mg/mL. If you mix it that way, your units will be different. Use the calculator to get the right draw for your vial.

Standard

Weeks 1–8

12u

300 mcg · Daily (5 on / 2 off)

AM, fasted, into abdominal fat. 300–500 mcg range; 300 is standard.

Off

4–8 weeks

Weekly 2-day break during the cycle helps avoid receptor desensitization.

Phase	How often	Dose	Units	Notes
Weeks 1–8	Daily (5 on / 2 off)	300 mcg	12u	AM, fasted, into abdominal fat. 300–500 mcg range; 300 is standard.
Off	4–8 weeks	–	–	Weekly 2-day break during the cycle helps avoid receptor desensitization.

Units column is labelled “Units (2.5 mg/mL)” on the page.

Cycle & timing

Cycle: 8–12 weeks on (5 days on / 2 off each week) / 4–8 weeks off.

Timing: First thing AM on an empty stomach, fasted state favors fat oxidation.

Where: SubQ, abdomen. Rotate.

What to expect

Subtle, gradual fat-loss support over 8–12 weeks; best as an adjunct to diet/training or stacked with a GLP-1 or GH peptide, not a standalone fix.

How much to buy

For 8-wk @ 300 mcg, 5/wk:

6

× 2mg vials

3

× 5mg vials

2

× 10mg vials

Men & women

Unisex (a GH fragment for fat loss without GH’s growth signaling), same protocol for men and women, no cycle effect. Avoid in pregnancy.

Dilution calculator

Set to the guide's typical mix for AOD-9604. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

6u

Volume

0.06 mL

Strength

5 mg/mL

Doses per vial

16

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
2 mg	0.4 mL	5 mg/mL
5 mg	1 mL	5 mg/mL
10 mg	2 mL	5 mg/mL

2 mg: 1 unit = 0.05 mg (50 mcg)

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, up to 4–6 weeks.

Don't use if: Pregnancy and lactation · Hypersensitivity to the peptide

Stop if you notice

Persistent injection-site reactions
Any unexpected systemic reaction
Pregnancy

Side effects

Generally minimal, occasional injection-site reaction or mild headache. No appetite, glucose, or IGF-1 effect.

Drug interactions

No significant known interactions. Stacks cleanly with GLP-1s and GH-axis peptides.

Labs

None compound-specific required; general metabolic panel if part of a larger fat-loss protocol. Weight / body-composition tracking.

What these labs mean →

Warnings

Does not raise IGF-1 or glucose, lacks the usual GH-class metabolic risks, but human efficacy data are modest. Quality varies between sources, request a COA. Marketed claims often exceed the evidence, treat as an adjunct.

Patient education

One of the gentler fat-loss peptides, no blood-sugar or IGF-1 impact. Effects are subtle; it works best alongside diet, training, or a stronger agent. Fasted AM dosing is standard. Source quality matters, request a COA.

These apply on top of the universal safety rules.

Pairs well with

Semaglutide / Tirzepatide

appetite + lipolysis

Semaglutide Tirzepatide

Tesamorelin / CJC + Ipamorelin

GH-axis fat loss

Tesamorelin Ipamorelin

Lipo-C / L-Carnitine

LC120 L-Carnitine

Avoid with

Pregnancy

No major interactions, one of the more benign fat-loss peptides

Can AOD-9604 + Semaglutide share a syringe?

Keep in separate syringes. GLP-1s run on their own weekly (or daily) schedule. Give them their own pin.

What it does

AOD-9604 is the C-terminal GH fragment (176–191). It stimulates lipolysis and inhibits lipogenesis via beta-3 adrenergic signaling without raising IGF-1 or affecting glucose, the key distinction from GH-axis peptides. Mild, additive fat-loss tool rather than a standalone heavyweight.

Note

Does not raise IGF-1 or glucose, so it lacks the GH-class metabolic warnings.

Approved drug

Approved weight-loss drugs are far better proven: semaglutide (Wegovy), tirzepatide (Zepbound), orforglipron (Foundayo, oral, 2026), plus phentermine, Qsymia, Contrave and orlistat.

References

researchdosing peptidedosages PubMed thepeptidereport

From the guide, page 17.